Skip to main content

Table 2 Molecular and clinical characteristics of patients with primary myelofibrosis (PMF)

From: A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients

Variables CALR mutation (n = 19) JAK2 mutation (n = 23) Triple Negative (n = 3) p-value
Males (%) 13 (68.4) 14 (60.9) 1 (33.3) 0.025*
Age,
Median (Range)
45 (37–70) 53 (21–76) 43 (22–60) 0.138
Haemoglobin (g/dL),
Median (Range)
10.5 (9.5–13.4) 9.8 (6.6–15) 7.9 (6.5–14.2) 0.45
TLC ×109/L,
Median (Range)
9.8 (5.6–63.2) 11.9 (1.8–22.1) 40.9 (15.1–25) 0.075
Platelet × 109/L,
Median (Range)
273 (122–1147) 382.5 (12–239) 131.5 (38–483) 0.358
Circulating blasts (%),
Median (Range)
29 47.5 (44–51) 38 0.306
Reticulin Fibrosis
MF 0 0 0 0  
MF 1 5 (26.3) 15 (65.2) 2 (66.7) 0.067
MF 2 14 (73.7) 8 (34.8) 1 (33.3)  
Constitutional symptoms (%) 12 (63.2) 14 (60.9) 3 (100) 0.421
DIPSS score, (%):
 Low 4 (21.1) 0 0  
 Intermediate-1 2 (10.5) 5 (21.7) 0 0.259
 Intermediate-2 9 (47.4) 15 (65.2) 3 (100)  
 High 4 (21.1) 3 (13) 0  
Leukemic transformation, (%) 2 (10.5) 2 (8.7) 1 (33.3) 0.629
  1. *significant